



**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 28 to 35 OF 2017**

Statements of Principles (SOPs) Nos. 28 to 35 of 2017 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 21 April 2017.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Statements of Principles is 22 May 2017. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from: <http://www.legislation.gov.au>.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Instrument, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The Authority has introduced significant change to the format of the SOPs determined by it under subsections 196B(2) and 196B(3) of the VEA. The changes were introduced to make the relationship between the provisions of the SOPs and the legislative framework for their creation and use clearer and to make them more accessible to users. The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new template. This document is available on the Authority's website <http://www.rma.gov.au>.

For further information contact:

The Registrar  
Repatriation Medical Authority  
GPO Box 1014  
Brisbane Qld 4001

T +61 7 3815 9404  
F +61 7 3815 9412  
E [info@rma.gov.au](mailto:info@rma.gov.au)

28 April 2017

## SUMMARY OF CHANGES

Instr. No.	Title	Date of Commencement	ICD-10-AM Codes
<b>REVOCATIONS</b>			
28 & 29/2017	thromboangiitis obliterans	22/05/2017	I73.1
30 & 31/2017	bronchiectasis	22/05/2017	Nil
32 & 33/2017	cardiac myxoma	22/05/2017	D15.1
<b>DETERMINATIONS</b>			
34 & 35/2017	immersion pulmonary oedema	22/05/2017	Nil

**SUMMARY OF CHANGES**

<p>28 &amp; 29/2017</p>	<p>thromboangiitis obliterans</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning <i>thromboangiitis obliterans</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 28/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'thromboangiitis obliterans' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factors in subsections 9(1) &amp; 9(4) concerning 'smoking', by the inclusion of a note;</li> <li>• new factors in subsections 9(2) &amp; 9(5) concerning 'second-hand smoke';</li> <li>• new factors in subsections 9(3) &amp; 9(6) concerning 'oral use of smokeless tobacco';</li> <li>• new definitions of 'being exposed to second-hand smoke', 'MRCA', 'smokeless tobacco' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'pack-year of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definition of 'pack years of cigarettes, or the equivalent thereof in other tobacco products'.</li> </ul> <p><b>For BoP SoP (Instrument No. 29/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'thromboangiitis obliterans' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factors in subsections 9(1) &amp; 9(2) concerning 'smoking', by the inclusion of a note;</li> <li>• new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'pack-year of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definition of 'pack years of cigarettes, or the equivalent thereof in other tobacco products'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>thromboangiitis obliterans</i> as advertised in the Government Notices Gazette of 3 May 2016.</b></p>
<p>30 &amp; 31/2017</p>	<p>bronchiectasis</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 September 2016 concerning <i>bronchiectasis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 30/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'bronchiectasis' in subsection 7(2);</li> <li>• revising the factor in subsection 9(1) concerning 'viral or bacterial pneumonia';</li> <li>• new factors in subsections 9(2) &amp; 9(24) concerning 'pertussis';</li> <li>• revising the factors in subsections 9(5) &amp; 9(27) concerning 'bronchial obstruction', by the inclusion of a note;</li> <li>• revising the factors in subsections 9(6) &amp; 9(28) concerning 'vapours, gases or fumes of a chemical agent';</li> <li>• new factors in subsections 9(7) &amp; 9(29) concerning 'occupational lung disease';</li> <li>• revising the factors in subsections 9(8) &amp; 9(30) concerning 'sulphur mustard (mustard gas)';</li> <li>• revising the factors in subsections 9(9) &amp; 9(31) concerning 'aspiration pneumonitis';</li> <li>• revising the factors in subsections 9(10) &amp; 9(32) concerning 'gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture';</li> </ul>

## SUMMARY OF CHANGES

- revising the factors in subsections 9(11) & 9(33) concerning 'allergic bronchopulmonary aspergillosis', by the inclusion of a note;
- revising the factors in subsections 9(12) & 9(34) concerning 'solid organ or bone marrow transplantation';
- revising the factors in subsections 9(13) & 9(35) concerning 'fibrosis or fibrosing interstitial lung disease';
- revising the factors in subsections 9(14) & 9(36) concerning 'arsenic', by the inclusion of a note;
- new factors in subsections 9(15) & 9(37) concerning 'connective tissue diseases';
- new factors in subsections 9(16) & 9(38) concerning 'human immunodeficiency virus';
- new factors in subsections 9(17) & 9(39) concerning 'haematological malignancy';
- new factors in subsections 9(18) & 9(40) concerning 'immunosuppressive drug';
- new factors in subsections 9(19) & 9(41) concerning 'human T-cell lymphotropic virus type 1';
- new factors in subsections 9(20) & 9(42) concerning 'inflammatory bowel disease';
- new factors in subsections 9(21) & 9(43) concerning 'severe and persistent asthma';
- new factors in subsections 9(22) & 9(44) concerning 'chronic obstructive pulmonary disease';
- revising the factor in subsection 9(23) concerning 'acute viral or bacterial lower respiratory tract infection';
- new definitions of 'immunosuppressive drug', 'MRCA', 'severe and persistent asthma', 'specified list of chemical agents', 'specified list of connective tissue diseases', 'specified list of occupational lung diseases' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'allergic bronchopulmonary aspergillosis', 'aspiration pneumonitis', 'being exposed to arsenic as specified', 'bronchial obstruction' and 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'inhaling toxic gases or fumes' and 'pneumonia'.

### ***For BoP SoP (Instrument No. 31/2017)***

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'bronchiectasis' in subsection 7(2);
- revising the factor in subsection 9(1) concerning 'viral or bacterial pneumonia';
- new factors in subsections 9(2) & 9(16) concerning 'pertussis';
- revising the factor in subsection 9(3) concerning 'pulmonary tuberculosis';
- revising the factors in subsections 9(5) & 9(19) concerning 'bronchial obstruction', by the inclusion of a note;
- revising the factors in subsections 9(6) & 9(20) concerning 'vapours, gases or fumes of a chemical agent';
- revising the factors in subsections 9(7) & 9(21) concerning 'aspiration pneumonitis';
- new factors in subsections 9(8) & 9(22) concerning 'gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture';
- revising the factors in subsections 9(9) & 9(23) concerning 'allergic bronchopulmonary aspergillosis', by the inclusion of a note;
- revising the factors in subsections 9(10) & 9(24) concerning 'solid organ or bone marrow transplantation';
- revising the factors in subsections 9(11) & 9(25) concerning 'fibrosis or fibrosing interstitial lung disease';
- new factors in subsections 9(12) & 9(26) concerning 'arsenic', by the inclusion of a note;
- new factors in subsections 9(13) & 9(27) concerning 'connective tissue diseases';
- new factors in subsections 9(14) & 9(28) concerning 'inflammatory bowel disease';
- revising the factor in subsection 9(15) concerning 'acute viral or bacterial lower respiratory tract infection';
- deleting the factors concerning 'sulphur mustard (mustard gas)' as they are now subsumed in the factors in subsections 9(6) & 9(20) concerning 'vapours, gases or fumes of a chemical agent';
- new definitions of 'being exposed to arsenic as specified', 'MRCA', 'specified list of chemical agents', 'specified list of connective tissue diseases' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'allergic bronchopulmonary aspergillosis', 'aspiration pneumonitis', 'bronchial obstruction' and 'relevant service' in Schedule 1 - Dictionary; and

**SUMMARY OF CHANGES**

		<ul style="list-style-type: none"> <li>deleting the definitions of 'inhaling toxic gases or fumes' and 'pneumonia'.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>bronchiectasis</i> as advertised in the Government Notices Gazette of 6 September 2016.</b></p>
32 & 33/2017	cardiac myxoma	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning <i>cardiac myxoma</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b><i>For RH &amp; BoP SoPs (Instrument Nos. 32 &amp; 33/2017)</i></b></p> <ul style="list-style-type: none"> <li>adopting the latest revised Instrument format, which commenced in 2015;</li> <li>specifying a day of commencement for the Instrument in section 2;</li> <li>revising the definition of 'cardiac myxoma' in subsection 7(2);</li> <li>revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>revising the factor in subsection 9(1) concerning 'heart transplant';</li> <li>new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and</li> <li>revising the definition of 'relevant service' in Schedule 1 - Dictionary.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>cardiac myxoma</i> as advertised in the Government Notices Gazette of 3 May 2016.</b></p>
34 & 35/2017	immersion pulmonary oedema	<p><b>New Condition</b></p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>immersion pulmonary oedema</i> as advertised in the Government Notices Gazette of 19 October 2016.</b></p>